Annual Report 2020

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY For the year ended 31 December 2020 42 The United Laboratories International Holdings Limited Annual Report 2020 Attributable to owners of the Company Foreign Non- Share Share Special Capital Revaluation exchange Retained controlling capital premium reserve reserve reserve reserve profits Subtotal interests Total RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 At 1 January 2019 15,346 2,437,831 277,100 846,217 95,616 3,274 2,446,658 6,122,042 – 6,122,042 Exchange differences arising on translation of a foreign operation – – – – – (1,971) – (1,971) – (1,971) Profit for the year – – – – – – 641,764 641,764 – 641,764 Total comprehensive (expense) income for the year – – – – – (1,971) 641,764 639,793 – 639,793 Dividends recognised as distribution (Note 15) – – – – – – (98,383) (98,383) – (98,383) Issue of shares upon conversion of convertible bonds (Note 30) 14 8,323 – – – – – 8,337 – 8,337 Transfer of revaluation reserve upon disposal of a subsidiary – – – – (95,616) – 95,616 – – – Appropriations – – – 88,575 – – (88,575) – – – At 31 December 2019 15,360 2,446,154 277,100 934,792 – 1,303 2,997,080 6,671,789 – 6,671,789 Exchange differences arising on translation of a foreign operation – – – – – 5,904 – 5,904 – 5,904 Profit (loss) for the year – – – – – – 702,989 702,989 (2,071) 700,918 Total comprehensive income (expense) for the year – – – – – 5,904 702,989 708,893 (2,071) 706,822 Dividends recognised as distribution (Note 15) – – – – – – (128,140) (128,140) – (128,140) Issue of shares upon conversion of convertible bonds (Note 30) 1,823 1,359,541 – – – – – 1,361,364 – 1,361,364 Appropriations – – – 100,585 – – (100,585) – – – At 31 December 2020 17,183 3,805,695 277,100 1,035,377 – 7,207 3,471,344 8,613,906 (2,071) 8,611,835